Cargando…

A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo

Functional aptamers displaying agonistic or antagonistic properties are showing great promise as modulators of immune responses. Here, we report the development of a polyethylene glycol-modified (PEGylated) DNA aptamer as a cross-species (murine and human) CD200R1 agonist that modulates inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prodeus, Aaron, Sparkes, Amanda, Fischer, Nicholas W., Cydzik, Marzena, Huang, Eric, Khatri, Ismat, Young, Ashley, Woo, Lindsay, Chow, Chung Wai, Gorczynski, Reginald, Gariépy, Jean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037911/ https://www.ncbi.nlm.nih.gov/pubmed/30195773 http://dx.doi.org/10.1016/j.omtn.2018.05.023

Ejemplares similares

Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival
por: Prodeus, Aaron, et al.
Publicado: (2014)

Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling
por: Gorczynski, Reginald M., et al.
Publicado: (2013)

Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model
por: Curry, Anna, et al.
Publicado: (2017)

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
por: Prodeus, Aaron, et al.
Publicado: (2015)

Characterization of CD200 Ectodomain Shedding
por: Wong, Karrie K., et al.
Publicado: (2016)

Can CD200R1 Agonists Slow the Progression of Osteoarthritis Secondary to Injury?
por: Vachhani, Kathak, et al.
Publicado: (2022)

Comparison of Immunity in Mice Cured of Primary/Metastatic Growth of EMT6 or 4THM Breast Cancer by Chemotherapy or Immunotherapy
por: Gorczynski, Reginald M., et al.
Publicado: (2014)

Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2
por: Wu, Florence TH, et al.
Publicado: (2015)

Agonistic nanobodies and antibodies to human VISTA
por: Ma, Yu-Heng Vivian, et al.
Publicado: (2021)

Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200
por: Gorczynski, Reginald M, et al.
Publicado: (2017)

Over-Expression of CD200 Protects Mice from Dextran Sodium Sulfate Induced Colitis
por: Chen, Zhiqi, et al.
Publicado: (2016)

Alternative splicing of CD200 is regulated by an exonic splicing enhancer and SF2/ASF
por: Chen, Zhiqi, et al.
Publicado: (2010)

Glypican-6 promotes the growth of developing long bones by stimulating Hedgehog signaling
por: Capurro, Mariana, et al.
Publicado: (2017)

A soluble activator that favors the ex vivo expansion of CD8(+)CD27(+) T cells
por: Matus, Esther I., et al.
Publicado: (2020)

Inmunología basada en la resolución de problemas
por: Gorczynski, Reginald M.
Publicado: (2007)

Toward a New Kind of Vaccine: A Logical Extension of the Symmetrical Immune Network Theory
por: Gorczynski, Reginald, et al.
Publicado: (2017)

The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies
por: Pilch, Zofia, et al.
Publicado: (2019)

The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity
por: Saha, Shrayasee, et al.
Publicado: (2023)

Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies
por: Akkaya, Munir, et al.
Publicado: (2013)

The Competition of Charge Remote and Charge Directed Fragmentation Mechanisms in Quaternary Ammonium Salt Derivatized Peptides—An Isotopic Exchange Study
por: Cydzik, Marzena, et al.
Publicado: (2011)

Computational design of a synthetic PD-1 agonist
por: Bryan, Cassie M., et al.
Publicado: (2021)

CD200fc enhances anti-tumoral immune response and inhibits visceral metastasis of breast carcinoma
por: Erin, Nuray, et al.
Publicado: (2018)

Serum‐derived exosomes from mice with highly metastatic breast cancer transfer increased metastatic capacity to a poorly metastatic tumor
por: Gorczynski, Reginald M., et al.
Publicado: (2016)

Health outcomes, education, healthcare delivery and quality – 3052. IL-17, IL-18, TGF-beta and GMCSF levels in patients with allergic asthma: Its relation to omalizumab treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

IL-8, IL-10, TGF-β, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti-IgE Treatment
por: Yalcin, Arzu D., et al.
Publicado: (2012)

Oncological Minimally Invasive Surgery
por: Huo, Qiang, et al.
Publicado: (2019)

Synthetic Siglec-9 agonists inhibit neutrophil activation associated with COVID-19
por: Delaveris, Corleone S., et al.
Publicado: (2020)

Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19
por: Delaveris, Corleone S., et al.
Publicado: (2021)

Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Environmental and occupational respiratory diseases – 1039. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

277 Serum Soluble Trail Levels in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Regulation of Circadian Behavior and Metabolism by Synthetic REV-ERB Agonists
por: Solt, Laura A., et al.
Publicado: (2012)

Computational Study of Synthetic Agonist Ligands of Ionotropic Glutamate Receptors
por: Wolter, Tino, et al.
Publicado: (2013)

Height, but not binding epitope, affects the potency of synthetic TCR agonists
por: Wilhelm, Kiera B., et al.
Publicado: (2021)

Height, but not binding epitope, affects the potency of synthetic TCR agonists
por: Wilhelm, Kiera B., et al.
Publicado: (2021)

Suppression of Pyk2 Kinase and Cellular Activities by Fip200
por: Ueda, Hiroki, et al.
Publicado: (2000)

Suppressing variation in synthetic circuits
por: Batchelor, Eric, et al.
Publicado: (2011)

CD200R signaling inhibits pro-angiogenic gene expression by macrophages and suppresses choroidal neovascularization
por: Horie, Shintaro, et al.
Publicado: (2013)

481 Differences in Humoral and Cellular Immunity in Young and Old Individuals
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2oufuf9lmeatqgf45ov5jpnid6